Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy

Jenny S W Yun¹, Chris McCormack¹, Michelle Goh¹ and Cherie Chiang²,³

¹Department of Surgical Oncology, ²Department of Internal Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, and ³University of Melbourne, Parkville, Victoria, Australia

Summary

Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma, in whom AN manifested after the first cycle of peptide receptor radionuclide therapy (PRRT). A 40-year-old man was diagnosed with metastatic insulinoma after 5 months of symptomatic hypoglycemia. Within 1 month post PRRT, the patient became euglycemic but developed a pigmented, pruritic rash which was confirmed on biopsy as AN. We discuss the rare manifestation of AN in subjects with insulinoma, the role of insulin in the pathogenesis of AN, malignant AN in non-insulin-secreting malignancies and association with other insulin-resistant endocrinopathies such as acromegaly.

Learning points:

- Acanthosis nigricans (AN) is a common dermatosis which is typically asymptomatic and associated with the hyperinsulinemic state.
- Malignant AN can rapidly spread, cause pruritus and affect mucosa and the oral cavity.
- AN is extremely rare in patients with insulinoma despite marked hyperinsulinemia.
- Peptide receptor radionuclide therapy might have triggered TGF-α secretion in this subject which led to malignant AN.
- Rapid spread or unusual distribution of pruritic AN warrants further investigation to exclude underlying malignancy.

Background

Acanthosis nigricans (AN) is a common dermatosis characterized by generalized cutaneous thickening with a pigmented velvety appearance (1). Although pathogenesis remains unclear, it is associated with hyperinsulinemic conditions such as type 2 diabetes and polycystic ovarian syndrome. Despite the marked persistent hyperinsulinemia seen in metastatic insulinoma, AN is a rarely reported. We report a case of metastatic insulinoma who developed symptomatic AN shortly after peptide receptor radionuclide therapy (PRRT) treatment. The resolution of AN was incongruent with circulating insulin concentration and disease progression. This prompts the possibility of malignant acanthosis nigricans (MAN), a rare paraneoplastic syndrome usually associated with non-insulin-producing adenocarcinoma which heralds a poor prognosis.
Case presentation

A 41-year-old man of Indian descent presented with 5 months of presyncopal episodes, diaphoresis and altered cognition. He gained 10 kg over 2 months leading up to the presentation (BMI = 32.3 kg/m²). Investigations captured a hypoglycemic episode with inappropriate hyperinsulinemia (plasma glucose = 2.4 mmol/L, insulin = 100.5 mU/mL (2.6–24.9 mU/mL), C-peptide = 2.28 nmol/L (0.3–2.3 nmol/L), HbA1c of 4.9%/26.8 mmol/mol). Imaging revealed primary pancreatic neuroendocrine tumor (NET) with FDG and 68-Gallium DOTATATE avid nodal metastasis. Immunohistochemistry of lymph node biopsy was positive for insulin, chromogranin and synaptophysin with a Ki-67 index of 10%. Octreotide, prednisolone and diazoxide were commenced for his grade 2 metastatic insulinoma. Within 1 month post 177Lu-DOTATATE (LuTate) PRRT, he observed hyperpigmented, pruritic skin changes on the hands, which rapidly progressed to involve neck, axillae and the lips (Fig. 1).

Investigation

Histopathological evaluation of skin biopsy confirmed acanthosis nigricans (Fig. 1). Post PRRT, the patient was mostly euglycemic as reflected by HbA1c of 6.3%/45.4 mmol/mol and plasma glucose of 5.5 mmol/L. Insulin (44.3 mU/mL) and C-peptide (1.45nmol/L) concentrations were reduced compared to baseline results.

Treatment

He completed four cycles of LuTate PRRT induction with a partial response on DOTATATE and FDG-PET imaging. He remained on prednisolone 10 mg and somatostatin analog therapy 12 months post PRRT.

Outcome and follow-up

Follow-up at 15 months post PRRT showed resolution of pruritus and fading of hyperpigmentation in the affected areas. However, he noted an increased frequency of hypoglycemia, and progressive disease was confirmed on functional imaging and biochemistry results (insulin = 109.6 mU/mL, c-peptide 3.69 nmol/L). Recurrent hypoglycemia persisted despite dexamethasone, 50% dextrose infusion, octreotide infusion and cytoreduction efforts with CAPTEM chemotherapy, everolimus and repeat PRRT induction. Patient deceased 2 years after the initial diagnosis of malignant insulinoma.

Discussion

AN is a common dermatosis characterized by brown to black velvety hyperpigmented lesions with symmetrical distribution in the skin folds such as groin, axilla or posterior neck, but it may also affect eyelids, lips and mucosal surfaces. It is generally asymptomatic and is more frequently observed in darker skin people (1). The etiology of AN is still not clearly defined, but it is likely related to hyperinsulinemia and insulin resistance. At high levels, insulin crosses the dermoepidermal junction, activates the insulin-like growth factor (IGF) receptor and reduces IGF binding proteins. Subsequently, increased free circulating IGF promotes local proliferation of keratinocytes and fibroblasts (2). AN may be associated with endocrine disorders including acromegaly, gigantism, polycystic ovarian syndrome, Cushing’s syndrome and type 2 diabetes. Medications such as glucocorticoids, insulin and estrogen can exacerbate hyperinsulinemia and lead to iatrogenic AN (3). In this setting, AN can resolve with improvement in insulin resistance via weight loss or by cessation of the offending medication (1).

In contrast, MAN is induced by malignancy (most commonly adenocarcinoma originating from the
Table 1  Summary of this case and other case reports of AN in insulinoma patients.

| Author            | Year | Age | Ethnicity/phototype | Gender | BMI (kg/m²) | Site of AN                   | Insulin (2.6–24.9 mU/mL) | C-peptide (0.3–2.3 nmol/L) | Benign vs metastatic/size of tumor (cm × cm) | Treatment/outcome of AN                                                                 |
|-------------------|------|-----|---------------------|--------|-------------|------------------------------|--------------------------|----------------------------|-------------------------------------------|----------------------------------------------------------------------------------|
| Pfeifer (11)      | 1999 | 16  | Caucasian           | Female | 39.8        | Neck, abdo, axillae          | 697                      | 3.645                      | Benign/N/A                              | Surgical excision/resolution of AN 11 years post operation                        |
| Tran (12)         | 2003 | 64  | N/A                 | Female | 43          | Eyes, lips, axillae, groin   | 171                      | 3.9                        | Metastatic/5.0 × 4.0                     | Surgical excision/N/A                                                               |
| Ghosh (13)        | 2008 | 35  | N/A                 | Male   | 31          | Neck                         | 79                       | 5.297                      | Benign/1.5 × 1.2                       | Surgical excision/resolution of AN 8 weeks post operation                        |
| Jyotsna (14)      | 2014 | 14  | Skin type 4         | Male   | 29          | N/A                          | 133.5                    | 4.019                      | Benign/1.8 × 1.1                       | Surgical excision/N/A                                                               |
| Patra (7)         | 2016 | 14  | Skin type 5         | Female | 36.5        | Neck                         | 16.8                     | 1.146                      | Benign/3.1 × 2.9                       | Surgical excision/significant reduction of AN 4 weeks post operation              |
| Gudala (15)       | 2017 | 15  | Hispanic            | Female | 32.8        | Neck, lips, neck, axillae, hands | 63.2                     | 1.821                      | Benign/1.2 × 1.2                       | Surgical excision/N/A                                                               |
| Yun (current case)| 2021 | 41  | Skin type 4         | Male   | 32.3        | Neck, lips, neck, axillae, hands | 100.5                    | 2.278                      | Metastatic/3.7 × 1.7 × 4.1             | PRRT/resolution of pruritus and improved hyperpigmentation                       |

N/A, not available.
gastrointestinal tract and pancreas) and can precede (18%), accompany (60%) or follow (22%) the onset of the malignancy. Visually indistinguishable from AN, these lesions are often pruritic, involve the oral cavity and have a rapid onset. The malignant tumor cells in the primary tumor and metastases secrete cytokines including transforming growth factor-α (TGF-α), IGF, fibroblast growth factor and α-melanocyte-stimulating hormone which pathologically stimulates fibroblasts, keratinocytes and melanocytes (4).

Insulinomas are rare neuroendocrine tumors, with an incidence of four cases per million patients per year. They are generally benign, but 5.8–15% are malignant tumors. In a series of 31 insulinoma patients, none had AN despite significant hyperinsulinemia (5). To date, there are only six case reports of AN and insulinoma (Table 1). Only half of the reviewed cases reported significant improvement and/or resolution of AN post-surgical enucleation of insulinoma. We did not find a temporal relationship between AN onset/severity and the circulating insulin concentration or tumor load in our case. AN was absent at diagnosis when his insulin was at its peak, thereafter AN appeared after PRRT treatment and then faded when disease progressed. Of the seven cases of AN and insulinoma in Table 1, the average insulin concentration was 181.7 mU/mL, a level typically seen in obese PCOS subjects post glucose load (6). Furthermore, other than our case, AN has only been reported in one other case with metastatic insulinoma. Therefore, AN in insulinoma patients might be a neoplastic phenomenon rather than an insulin hypersecretion issue per se. Patra et al. also questioned hyperinsulinemia as the sole mechanism given the rare prevalence of AN in insulinoma patients (7).

To our knowledge, our case is the first described case of AN observed after the commencement of insulinoma treatment. PRRT is a relatively new mode of therapy for malignant insulinomas. The first cycle of PRRT can trigger a peptide storm as the targeted insulin-producing neuroendocrine cells die, resulting in transient insulin release and potentially intractable hypoglycemia (8). TGF-α expression has been demonstrated in NETs (9). Large quantities of TGF-α can bind to the EGF receptor to promote proliferation and differentiation of keratinocytes, thereby leading to AN. It is plausible that the peptidome secretion post PRRT triggered the AN in our case (10).

In summary, we report a rare manifestation of AN post PRRT treatment for malignant insulinoma. The temporal course, rapid onset and distribution suggest MAN due to peptidome secretion post PRRT rather than insulin hypersecretion as a cause. Since AN is common amongst patients with obesity or diabetes, clinicians should be wary of atypical AN presentation which might uncover the underlying malignancy.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Patient consent
The patient provided written informed consent for publication of the submitted article and accompanying deidentified images.

Author contribution statement
J Y collected data and composed the manuscript, and the senior co-authors C C, C M and M G assisted with the analysis and provided critical revision of the manuscript for important intellectual content.

References
1 Popa ML, Popa AC, Tanase C & Gheorghisan-Galateanu AA. Acanthosis nigricans: to be or not to be afraid. Oncology Letters 2019 17 4133–4138. (https://doi.org/10.3892/ol.2018.9736)
2 González-Saldivar G, Rodríguez-Gutierrez R, Ocampo-Candiani J, González-González G, Gómez-Flores R. Skin manifestations of insulin resistance: from a biochemical stance to a clinical diagnosis and management. Dermatology and Therapy 2017 7 37–51. (https://doi.org/10.1007/s13555-016-0160-3)
3 Mourad Al & Haber RM. Drug-induced acanthosis nigricans: a systematic review and new classification. Dermatologic Therapy 2021 34 e14794. (https://doi.org/10.1111/dth.14794)
4 James WD, Elston D, Treat JR, Rosenbach MA & Neuhaus IM. Andrews’ Diseases of the Skin, 13th ed, pp. 496–504. London: Elsevier, 2020. (ISBN 9780323547536)
5 Jyotsna VP, Rangel N, Pal S, Seith A, Sahni P & Ammini AC. Insulinoma: diagnosis and surgical treatment: retrospective analysis of 31 cases. Indian Journal of Gastroenterology 2006 25 244–247. (https://pubmed.ncbi.nlm.nih.gov/17090842/)
6 Morin-Papunen LC, Vauhkonen J, Koivunen RM, Ruokonen A & Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Human Reproduction 2000 15 1266–1274. (https://doi.org/10.1093/humrep/15.6.1266)
7 Patra S, Chakraborty PP, Barman H & Santra G. Acanthosis nigricans in insulinoma: before and after successful surgical enucleation. BMJ Case Reports 2016 2016 bcr2016218003. (https://doi.org/10.1136/bcr-2016-218003)
8 Del Olmo-García MI, Muros MA, López-de-la-Torre M, Agudelo M, Bello P, Soriano JM & Merino-Torres JE. Prevention and management of hormonal crisis during therapy with LU-DOTA-TATE in neuroendocrine tumors: a systematic review and approach proposal. Journal of Clinical Medicine 2020 9 2203. (https://doi.org/10.3390/jcm9072203)
9 Nilsson O, Wångberg B, Kolby L, Schultz GS & Ahlman H. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. *International Journal of Cancer* 1995 60 645–651. (https://doi.org/10.1002/ijc.2910600514)

10 Kay RG, Challis BG, Casey RT, Roberts GP, Meek CL, Reimann F & Gribble FM. Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours. *Rapid Communications in Mass Spectrometry* 2018 32 1414–1424. (https://doi.org/10.1002/rcm.8183)

11 Pfeifer SL, Wilson RM & Gawkrodger DJ. Clearance of acanthosis nigricans associated with the HAIR-AN syndrome after partial pancreatectomy: an 11-year follow-up. *Postgraduate Medical Journal* 1999 75 421–422. (https://doi.org/10.1136/pgmj.75.885.421)

12 Tran TH, Pathak RD & Basa AL. Metastatic insulinoma: case report and review of the literature. *Southern Medical Journal* 2004 97 199–201. (https://doi.org/10.1097/01.SMJ.0000091035.18498.47)

13 Ghosh S, Roychowdhury B, Mukhopadhay S & Chowdhury S. Clearance of acanthosis nigricans associated with insulinoma following surgical resection. *QJM: Monthly Journal of the Association of Physicians* 2008 101 899–900. (https://doi.org/10.1093/qjmed/hcn098)

14 Jyotsna VP, Raizada N, Chakraborty S & Pal S. Acanthosis nigricans in insulinoma. *Indian Journal of Endocrinology and Metabolism* 2014 18 739. (https://doi.org/10.4103/2230-8210.139223)

15 Gudala M, Ahmed M, Conroy R & Tonyushkina K. Insulinoma masquerading as a loss of consciousness in a teenage girl: case report and literature review. *International Journal of Pediatric Endocrinology* 2017 13. (https://doi.org/10.1186/s13633-017-0049-7)

Received in final form 3 April 2022
Accepted 11 May 2022